Everio Airmaster

Everio Airmaster combines Fluticasone Propionate and Salmeterol Xinafoate for inhalation use. It is designed to manage respiratory conditions by reducing inflammation and relaxing airway muscles. This medication is manufactured by Zentiva, K.S., an EU-based pharmaceutical company.

Everio Airmaster is primarily used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). The combination of Fluticasone Propionate, a corticosteroid, and Salmeterol Xinafoate, a long-acting beta-agonist, works to reduce airway inflammation and prevent bronchospasms. This medication is often prescribed to individuals who require both an anti-inflammatory and a bronchodilator for effective respiratory management.

Common effects of Everio Airmaster may include throat irritation, hoarseness, and a dry mouth. Some users might experience headaches, tremors, or an increased heart rate. These effects are generally mild and temporary, but persistent or severe symptoms should be discussed with a healthcare provider.

Everio Airmaster should be used as directed by a healthcare professional. It is important to rinse your mouth after each use to minimize the risk of oral thrush. Patients with certain medical conditions, such as heart disease or diabetes, should use this medication with caution. Always inform your healthcare provider about any existing health conditions or medications you are taking.

Everio Airmaster may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is advisable to avoid using this medication with other long-acting beta-agonists without medical supervision. Additionally, the use of alcohol or other respiratory depressants should be discussed with a healthcare provider to prevent potential adverse effects.